Claim 50% Off TipRanks Premium and Invest with Confidence
- Unlock hedge-fund level data and powerful investing tools designed to help you make smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis so your portfolio is always positioned for maximum potential
Trellus Health PLC ( (GB:TRLS) ) just unveiled an announcement.
Trellus Health PLC has announced updates regarding its financial and operational strategies, including extending its cash runway to early December 2025 through cost-saving measures and reducing its monthly cash burn. The company is in late-stage contract negotiations for a collaboration with a leading global CRO, which could enhance its positioning in the clinical trials sector. Additionally, Trellus Health is exploring potential equity fundraising to support future growth, though no definitive funding transactions have been concluded yet.
More about Trellus Health PLC
Trellus Health PLC is a healthcare company that offers innovative, value-based solutions and services aimed at helping individuals with chronic conditions manage their health. The company provides a scientifically validated self-management solution and personalized support through its Trellus Elevate® platform, focusing initially on chronic gastrointestinal conditions like Inflammatory Bowel Disease (IBD). Trellus Health’s approach has demonstrated significant reductions in hospitalizations and emergency room visits among IBD patients. The company also offers Trellus TrialSet™, a solution for pharmaceutical partners that supports clinical trials and patient engagement.
Average Trading Volume: 1,276,637
Technical Sentiment Signal: Sell
Current Market Cap: £1.21M
See more data about TRLS stock on TipRanks’ Stock Analysis page.